Mesoblast, Inc.
Nasdaq MESO · Melbourne, Victoria, Australia
Works in Cardiovascular · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Oncology · Respiratory
Mesoblast, Inc. is a clinical trial sponsor based in Melbourne, Victoria, Australia, listed as Nasdaq MESO. It has 2 active clinical trials with 480 planned participants, across 9 therapeutic areas. Since 2021 it has completed 15 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq MESO
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Mesoblast, Inc
Mesoblast, Inc is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 480 planned participants, in Cardiovascular, GI & liver, Hematology, Immunology and other areas. Since 2021 it has completed 15 trials and stopped 0 early.
Mesoblast, Inc is based in Melbourne, Victoria, Australia and is listed as Nasdaq MESO. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Mesoblast, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-06-17.
Approve Suite is not affiliated with Mesoblast, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.